# Lipiodol as an Imaging Biomarker in Patients With Primary and Metastatic Liver Cancer

> **NCT01877187** · PHASE2 · COMPLETED · sponsor: **Yale University** · enrollment: 39 (actual)

## Conditions studied

- Liver Cancer

## Interventions

- **DRUG:** Lipiodol

## Key facts

- **NCT ID:** NCT01877187
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2020-02
- **Final completion:** 2020-02
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2020-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01877187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01877187, "Lipiodol as an Imaging Biomarker in Patients With Primary and Metastatic Liver Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01877187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*